Hypertension in people with type 2 diabetes: Update on pharmacologic management;L'hypertension chez les diabétiques de type 2: Mise à jour sur le traitement pharmacologique

Canadian Family Physician

Volumn 57, Issue 9, 2011, Pages

  Campbell, Norm R C ^a   Gilbert, Richard E ^b   Leiter, Lawrence A ^b   Larochelle, Pierre ^c   Tobe, Sheldon ^d   Chockalingam, Arun ^e   Ward, Richard ^f   Morris, Dorothy ^g   Tsuyuki, Ross T ^h   Harris, Stewart B ⁱ  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g VANCOUVER ISLAND HEALTH AUTHORITY   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; POTASSIUM; SODIUM; SPIRONOLACTONE;

ABDOMINAL OBESITY; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL STUDY; COMORBIDITY; CORONARY ARTERY DISEASE; COST MINIMIZATION ANALYSIS; DIET; DIET RESTRICTION; DISABILITY; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; EYE DISEASE; GENETIC PREDISPOSITION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; INFORMATION RETRIEVAL; KIDNEY FAILURE; LEG AMPUTATION; MACROALBUMINURIA; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; POTASSIUM BLOOD LEVEL; PRESCRIPTION; PRIMARY PREVENTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEDENTARY LIFESTYLE; SODIUM RETENTION; STROKE; SYNCOPE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PRIMARY HEALTH CARE;

EID: 80053027027     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Agence de la santé publique du Canada. Report from the Canadian Chronic Disease Surveillance System: hypertension in Canada, 2010. Ottawa, ON: Agence de la santé publique du Canada; 2010. Accessible à: www.phac-aspc.gc.ca/cd-mc/cvd-mcv/ccdss-snsmc-2010/index-eng.php. Accédé le 13 juillet 2011.
2. Agence de la santé publique du Canada. Report from the National Diabetes Surveillance System: diabetes in Canada, 2009. Ottawa, ON: Agence de la santé publique duCanada; 2009. Accessible à: www.phac-aspc.gc.ca/ publicat/2009/ndssdic-snsddac-09/index-eng.php. Accédé le 13 juillet 2011
3. Comité d'experts des lignes directrices de pratique clinique de l'Association canadienne du diabète. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-201. Accessible à: www.diabetes.ca/files/cpg2008/cpg-2008.pdf. Accédé le13 juillet 2011.
4. Bild D, Teutsch SM. The control of hypertension in persons with diabetes: a public health approach. Public Health Rep 1987;102(5):522-9. (Pubitemid 17156804)
5. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37(4):1053-9. (Pubitemid 32304003)
6. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et collab. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9.
7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et collab. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60.
8. McInnis NH, Fodor G, Lum-Kwong MM, Leenen FH. Antihypertensive medication use and BP control: a community-based cross-sectional survey (ON-BP). Am J Hypertens 2008;21(11):1210-5. Cyberpub. du 4 septembre 2008.
9. Leenen FH, Dumais J, McInnis NH, Turton P, Stratychuk L, Nemeth K et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008;178(11):1441-9. (Pubitemid 351775721)
10. Campbell NR, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J et collab. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension 2009;53(2):128-34. Cyberpub. du 29 décembre 2008.
11. McAlister FA, Feldman RD, Wyard K, Brant R, Campbell NR; CHEP Outcomes Research Task Force. The impact of the Canadian Hypertension Education Programme in its first decade. Eur Heart J 2009;30(12):1434-9. Cyberpub. du 19 mai 2009.
12. Zarnke KB, Campbell NR, McAlister FA, Levine M; Canadian Hypertension Recommendations Working Group. A novel process for updating recommendations for managing hypertension: rationale and methods. Can J Cardiol 2000;16(9):1094-102.
13. Tobe SW, Touyz RM, Campbell NR; Canadian Hypertension Education Program. The Canadian Hypertension Education Program - a unique Canadian knowledge translation program. Can J Cardiol 2007;23(7):551-5. (Pubitemid 46971158)
14. Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR et collab. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 2010;26(5):249-58.
15. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2):434-44. (Pubitemid 23046633)
16. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S et collab. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005;46(1):156-61. Cyberpub. du 6 juin 2005.
17. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160):703-13.
18. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61(3):1086-97. (Pubitemid 34175478)
19. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-64. (Pubitemid 30185779)
20. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et collab. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829-40. (Pubitemid 47362321)
21. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355(9200):253-9.
22. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ et collab. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340(9):677-84. (Pubitemid 29110751)
23. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et collab. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351(9118):1755-62. (Pubitemid 28269185)
24. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J et collab. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;5(12):1410-9. (Pubitemid 40973424)
25. Neutel CI, Morrison H, Campbell NR, De Groh M. Statin use in Canadians: trends, determinants and persistence. Can J Public Health 2007;98(5):412-6.
26. ACCORD Study Group; Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr et collab. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1575-85. Cyberpub. du 14 mars 2010.
27. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB et collab. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010;56(1):77-85.
28. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB et collab. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165(12):1401-9. (Pubitemid 40973423)
29. Pool JL. Is it time to move to multidrug combinations? Am J Hypertens 2003;16(11 Pt 2):36S-40S. (Pubitemid 37449437)
30. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et collab. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372(9638):547-53.
31. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I et collab. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59. Cyberpub. du31 mars 2008.
32. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et collab. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359(23):2417-28.
33. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et collab. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36(3):646-61.
34. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002;39(5):982-8. (Pubitemid 34547797)
35. Agarwal R. Hypertension, hypokalemia, and thiazide-induced diabetes: a 3-way connection. Hypertension 2008;52(6):1012-3. Cyberpub. du 3 novembre 2008.
36. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000;35(5):1025-30. (Pubitemid 30327250)
37. CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287(19):2542-51.
38. Wiklund I, Halling K, Rydén-Bergsten T, Fletcher A. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997;6(6):357-64. (Pubitemid 28078825)
39. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86. Erratum dans: BMJ 2002;324(7330):141.
40. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N et collab. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300(18):2134-41. Cyberpub. du 9 novembre 2008.
41. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R et collab. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840. DOI: 10.1136/bmj.a1840.
42. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358(6):580-91. (Pubitemid 351214285)